Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Accessibility of cortical regions to focal TES: Dependence on spatial position, safety, and practical constraints

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intensive screening for osteoporosis in patients with hip fracture

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: There is a large unmet need for treatments for patients with progressive multiple sclerosis (MS). Phase 2 studies with cerebrospinal fluid (CSF) biomarker outcomes may be well suited for the initial evaluation of efficacious treatments.

OBJECTIVE: To evaluate the effect of monthly oral methylprednisolone pulse treatment on intrathecal inflammation in progressive MS.

METHODS: In this open-label phase 2A study, 15 primary progressive and 15 secondary progressive MS patients received oral methylprednisolone pulse treatment for 60 weeks. Primary outcome was changes in CSF concentrations of osteopontin. Secondary outcomes were other CSF biomarkers of inflammation, axonal damage and demyelination; clinical scores; magnetic resonance imaging measures of disease activity, magnetization transfer ratio (MTR) and diffusion tensor imaging (DTI); motor evoked potentials; and bone density scans.

RESULTS: We found no change in the CSF concentration of osteopontin, but we observed significant improvement in clinical scores, MTR, DTI and some secondary CSF outcome measures. Adverse events were well-known side effects to methylprednisolone.

CONCLUSION: Monthly methylprednisolone pulse treatment was safe, but had no effect on the primary outcome. However, improvements in secondary clinical and MRI outcome measures suggest that this treatment regimen may have a beneficial effect in progressive MS.

Original languageEnglish
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
Volume22
Issue number7
Pages (from-to)926-934
Number of pages9
ISSN1352-4585
DOIs
Publication statusPublished - Jun 2016

ID: 45677587